Comparison of Chemoradiotherapy Followed by Planned Surgery Versus Chemoradiotherapy With Surgery as Needed for Treating Locally Advanced Esophageal Squamous Cell Carcinoma
Led by Karolinska University Hospital · Updated on 2025-03-06
1020
Participants Needed
12
Research Sites
260 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are comparing two treatment approaches for patients with resectable locally advanced squamous cell carcinoma of the esophagus. The trial aims to assess overall survival, quality of life, and eating restrictions after different chemoradiotherapy and surgery strategies. This phase III, randomized, open-label study hopes to guide future clinical practice for this condition.
One group receives neoadjuvant chemoradiotherapy followed by planned esophagectomy. Radiotherapy is delivered in 1.8 Gy fractions five days a week for 23 sessions, combined with weekly carboplatin and paclitaxel chemotherapy. The second group undergoes definitive chemoradiotherapy with surveillance esophagectomy is performed only if cancer remains or recurs. Radiotherapy in this group follows one of two dosing schedules, combined with one of three chemotherapy regimens including carboplatin-paclitaxel, cisplatin-5-fluorouracil, or FOLFOX.
Participants are monitored for overall survival three years after randomization, and their global health-related quality of life and eating restrictions one year after starting treatment. Additional assessments include quality of life evaluations up to five years, event-free survival, relapse rates, treatment side effects, surgical complications, and nutritional outcomes. The study involves repeated evaluations and follow-up over several years to capture long-term effects of the treatments.
CONDITIONS
Brief Title
Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer
Research Team
M
Magnus Nilsson, MD, PhD
M
Mats Hellström
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Histopathologically confirmed squamous cell carcinoma of the esophagus in locally advanced stages cT1 N+ or cT2-4a any N, M0 according to AJCC TNM classification
Disease must be technically resectable as determined by local multidisciplinary team
Performance status ECOG 0 or 1
Adequate organ function
Women of childbearing potential must have a negative pregnancy test
Use highly effective birth control during treatment and for 5 months after last study treatment
Breastfeeding women must stop nursing before starting treatment
No psychological, familial, sociological, or geographical conditions that would prevent compliance or follow-up
Written informed consent provided before randomization
You will not qualify if you...
Distant metastases (M1) according to AJCC TNM classification
Tumors classified as cT4b
Primary tumor not resectable without laryngectomy
Impaired kidney, liver, heart, lung, or endocrine function that prevents multimodality treatment
Patients unlikely to tolerate chemoradiotherapy followed by esophagectomy
Previous malignancies unless disease-free for at least 5 years
Prior or overlapping radiotherapy or chemoradiotherapy
Known uncontrollable allergy to chemotherapy components used in the trial
Inability to understand study information or comply due to language or cognitive difficulties such as dementia or severe psychiatric disorder
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Treatment
Duration - Approximately 5 to 6 weeks of chemoradiotherapy; surgery within 8 weeks after chemoradiotherapy or as needed
Participants receive chemoradiotherapy according to their assigned arm. Arm A involves neoadjuvant chemoradiotherapy followed by planned surgery within 8 weeks after treatment. Arm B involves definitive chemoradiotherapy followed by surveillance and surgery only if residual or recurrent cancer occurs.
Weekly visits during chemoradiotherapy; surgery visit if applicable
Surveillance
Duration - Up to several years after chemoradiotherapy
Participants in the surveillance arm are monitored for residual or recurrent cancer and may undergo surgery if needed.
Follow-up visits at multiple timepoints up to 5 years after randomization
Follow-up
Duration - Up to 5 years after randomization
Participants are monitored for overall survival, quality of life, treatment-related events, and nutritional outcomes up to 5 years after randomization.
Visits at 6, 12, 24, 36, and 60 months after randomization
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Study of Sintilimab as Additional Treatment After Surgery for Node-Positive Esophageal Squamous Cell Carcinoma Without Prior Therapy
Study on Using Pre-treatment Tumor Biopsies to Predict Response to PD-1PD-L1 Immunotherapy in Various Cancers
Evaluating TER-2013 Alone and with Fulvestrant for Solid Tumors with AKTPI3KPTEN Pathway Alterations in a Phase 12 Trial
Evaluating Itraconazole Added to Standard Chemoradiation or Chemoimmunotherapy and Surgery in Resectable Esophageal and Gastroesophageal Junction Cancer
Phase IbII Study of Ivonescimab AK112 with Albumin-Paclitaxel and Cisplatin as Pre-Surgery Treatment for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
Phase III Trial Comparing Chemoradiotherapy with and without Prophylactic Irradiation for Early-Stage Esophageal Squamous Cell Carcinoma
Evaluating Safety, Effectiveness, and Dosing of EVOLVE104 for Advanced Urothelial and Squamous Cell Cancers in a Phase 1 Study
Evaluating BL-B01D1 with Tislelizumab With or Without 5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab
as First-Line Treatment for Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Comparing Chemoradiation Plus Tislelizumab Versus Chemotherapy Plus Tislelizumab
as First Treatment for Advanced Esophageal Squamous Cell Carcinoma with Low PD-L1
Phase 1 Study of IDE034 to Assess Safety and Effectiveness in Adults With Advanced or Metastatic Solid Tumors Expressing B7-H3 and PTK7
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial.
Magnus Nilsson, Halla Olafsdottir, Gabriella Alexandersson von Döbeln...